These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25064681)

  • 1. Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study.
    Zhang Z; Zhai J; Wei Q; Qi J; Guo X; Zhao J
    BMC Psychiatry; 2014 Jul; 14():212. PubMed ID: 25064681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study.
    Guo X; Zhai J; Liu Z; Fang M; Wang B; Wang C; Hu B; Sun X; Lv L; Lu Z; Ma C; He X; Guo T; Xie S; Wu R; Xue Z; Chen J; Twamley EW; Jin H; Zhao J
    Arch Gen Psychiatry; 2010 Sep; 67(9):895-904. PubMed ID: 20819983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model.
    Jin H; Tappenden P; MacCabe JH; Robinson S; Byford S
    JAMA Netw Open; 2020 May; 3(5):e205888. PubMed ID: 32459356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).
    Karow A; Reimer J; König HH; Heider D; Bock T; Huber C; Schöttle D; Meister K; Rietschel L; Ohm G; Schulz H; Naber D; Schimmelmann BG; Lambert M
    J Clin Psychiatry; 2012 Mar; 73(3):e402-8. PubMed ID: 22490266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
    Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
    J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT.
    Morrison AP; Pyle M; Gumley A; Schwannauer M; Turkington D; MacLennan G; Norrie J; Hudson J; Bowe S; French P; Hutton P; Byrne R; Syrett S; Dudley R; McLeod HJ; Griffiths H; Barnes TR; Davies L; Shields G; Buck D; Tully S; Kingdon D
    Health Technol Assess; 2019 Feb; 23(7):1-144. PubMed ID: 30806619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
    Park T; Kuntz KM
    Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study).
    Hastrup LH; Kronborg C; Bertelsen M; Jeppesen P; Jorgensen P; Petersen L; Thorup A; Simonsen E; Nordentoft M
    Br J Psychiatry; 2013 Jan; 202(1):35-41. PubMed ID: 23174515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.
    Järbrink K; Kreif N; Benedict A; Locklear J
    Curr Med Res Opin; 2009 Mar; 25(3):709-16. PubMed ID: 19196221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
    Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
    Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.